Key PointsPfizer's numbers were strong in its most recent quarter, with both its top and bottom lines coming in better than analyst forecasts.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.